Nestlé Health Science and EraCal Therapeutics Ltd today announced that they entered into a research collaboration aiming to identify novel nutraceuticals relevant to control food intake. The joint program combines Nestle’s unique nutraceutical resources with EraCal’s differentiated drug discovery platform. These synergies aim to provide a new paradigm for first-line nutraceuticals for people suffering from metabolic diseases.
Traditional research strategies (cell lines, organoids, etc) cannot capture whole-organism, multifactorial dynamics associated with metabolic diseases. EraCal‘s custom-built platform overcomes these challenges by combining state-of-the-art microscopy with the power of large-scale phenotypic drug discovery. The platform is peer-reviewed , demonstrates translational success with diverse pharmaceutical modalities, and therefore holds the promise to unlock new biology. The platform has identified novel mechanisms of action and is therefore a prime choice to discover first-in-class compounds.
EraCal Therapeutics Ltd. is a Swiss biotech startup developing a novel anti-obesity drug candidate. It was founded in September 2018 by former UZH Entrepreneur fellow Josua Jordi and Simon Breitler as an UZH-spin-off. Nestlé Health Science is a globally managed business unit of Nestlé.